Dapagliflozin and Cardiac Reverse Remodeling: New Insights in the Mechanistic Puzzle of SGLT2 Inhibitors.
作者信息
Chatur Safia, Churchill Timothy W
机构信息
Division of Cardiology, Massachusetts General Hospital, Boston, Massachusetts; Cardiac Ultrasound Laboratory, Massachusetts General Hospital, Boston, Massachusetts.
Division of Cardiology, Massachusetts General Hospital, Boston, Massachusetts; Cardiac Ultrasound Laboratory, Massachusetts General Hospital, Boston, Massachusetts; Cardiovascular Performance Program, Massachusetts General Hospital, Boston, Massachusetts.
出版信息
J Am Soc Echocardiogr. 2025 May;38(5):404-408. doi: 10.1016/j.echo.2025.01.002. Epub 2025 Jan 6.
Abstract
摘要
相似文献
1
Dapagliflozin and Cardiac Reverse Remodeling: New Insights in the Mechanistic Puzzle of SGLT2 Inhibitors.
J Am Soc Echocardiogr. 2025 May;38(5):404-408. doi: 10.1016/j.echo.2025.01.002. Epub 2025 Jan 6.
2
Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts.
Free Radic Biol Med. 2017 Mar;104:298-310. doi: 10.1016/j.freeradbiomed.2017.01.035. Epub 2017 Jan 26.
3
Effects of the SGLT2 Inhibition on Cardiac Remodeling in Streptozotocin-Induced Diabetic Rats, a Model of Type 1 Diabetes Mellitus.
Antioxidants (Basel). 2022 May 17;11(5):982. doi: 10.3390/antiox11050982.
4
Analysis of the efficacy of SGLT2 inhibitors using semi-mechanistic model.
Front Pharmacol. 2014 Oct 13;5:218. doi: 10.3389/fphar.2014.00218. eCollection 2014.
5
Dapagliflozin protects against chronic heart failure in mice by inhibiting macrophage-mediated inflammation, independent of SGLT2.
Cell Rep Med. 2023 Dec 19;4(12):101334. doi: 10.1016/j.xcrm.2023.101334.
6
Peripartum dapagliflozin improves late-life maternal cardiovascular outcomes in a murine model of superimposed preeclampsia.
Am J Obstet Gynecol. 2025 Mar 29. doi: 10.1016/j.ajog.2025.03.035.
7
Comparative Pharmacokinetics and Pharmacodynamics of a Novel Sodium-Glucose Cotransporter 2 Inhibitor, DWP16001, with Dapagliflozin and Ipragliflozin.
Pharmaceutics. 2020 Mar 15;12(3):268. doi: 10.3390/pharmaceutics12030268.
8
Acute antiarrhythmic effects of SGLT2 inhibitors-dapagliflozin lowers the excitability of atrial cardiomyocytes.
Basic Res Cardiol. 2024 Feb;119(1):93-112. doi: 10.1007/s00395-023-01022-0. Epub 2024 Jan 3.
9
Dapagliflozin Does Not Protect against Adriamycin-Induced Kidney Injury in Mice.
Kidney Blood Press Res. 2024;49(1):81-90. doi: 10.1159/000536088. Epub 2024 Jan 5.
10
Dapagliflozin effects on exercise, cardiac remodeling, biomarkers, and renal and pulmonary function in heart failure patients: not as good as expected?
Front Cardiovasc Med. 2025 Mar 17;12:1542870. doi: 10.3389/fcvm.2025.1542870. eCollection 2025.
引用本文的文献
1
Heart Failure and Wide QRS: Clinical and Pharmacological Perspectives.
Biomedicines. 2025 Jun 13;13(6):1462. doi: 10.3390/biomedicines13061462.
本文引用的文献
1
Empagliflozin to prevent worsening of left ventricular volumes and systolic function after myocardial infarction (EMPRESS-MI).
Eur J Heart Fail. 2025 Mar;27(3):566-576. doi: 10.1002/ejhf.3560. Epub 2024 Dec 15.
2
Harnessing SGLT2 Inhibitors: A New Frontier in Cardiac Remodeling for Nondiabetic Heart Failure.
JACC Cardiovasc Imaging. 2024 Dec;17(12):1409-1410. doi: 10.1016/j.jcmg.2024.09.007.
3
Dapagliflozin Effects on Left Ventricular Remodeling and Filling Pressures in Heart Failure With Reduced Ejection Fraction.
J Am Soc Echocardiogr. 2025 May;38(5):395-403. doi: 10.1016/j.echo.2024.10.009. Epub 2024 Oct 28.
4
Dapagliflozin Effects on Cardiac Deformation in Heart Failure and Secondary Clinical Outcome.
JACC Cardiovasc Imaging. 2024 Dec;17(12):1399-1408. doi: 10.1016/j.jcmg.2024.05.014. Epub 2024 Jul 17.
5
Left Atrioventricular Coupling Index: A Novel Diastolic Parameter to Refine Prognosis in Heart Failure.
J Am Soc Echocardiogr. 2024 Nov;37(11):1038-1046. doi: 10.1016/j.echo.2024.06.013. Epub 2024 Jun 29.
6
Efficacy and Safety of Empagliflozin According to Background Diuretic Use in HFrEF: Post-Hoc Analysis of EMPEROR-Reduced.
JACC Heart Fail. 2024 Jan;12(1):35-46. doi: 10.1016/j.jchf.2023.06.036. Epub 2023 Sep 13.
7
Safety and Efficacy of Empagliflozin and Diuretic Use in Patients with Heart Failure and Preserved Ejection Fraction: A Post Hoc Analysis of the EMPEROR-Preserved Trial.
JAMA Cardiol. 2023 Jul 1;8(7):640-649. doi: 10.1001/jamacardio.2023.1090.
8
Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial.
Eur Heart J. 2023 Aug 14;44(31):2930-2943. doi: 10.1093/eurheartj/ehad283.
9
Impact of dapagliflozin on cardiac remodelling in patients with chronic heart failure: The DAPA-MODA study.
Eur J Heart Fail. 2023 Aug;25(8):1352-1360. doi: 10.1002/ejhf.2884. Epub 2023 Jun 7.
10
Effects of Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients with Chronic Kidney Disease: The DECODE-CKD Trial.
Kidney360. 2023 Feb 1;4(2):143-149. doi: 10.34067/KID.0006982022. Epub 2022 Dec 18.
Zotero 插件